Market data loadingS&P 500--NASDAQ--Data as of latest ETNo timestamp

HCA Healthcare, Inc. (HCA) SEC Filings & Earnings Calls

EquiReason read 18 HCA Healthcare, Inc. SEC filings in the last 12 months. Latest: 8-K on 2026-07-29 — HCA Inc. increased commercial paper program from $4.0B to $8.0B; notes unsecured, guaranteed by parent..

Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason

HCAHCA Healthcare, Inc.Follow HCA — free
Medical Care Facilities · Healthcare
—
Price chart with a free account
Market cap
101.5B
P/E TTM
15.7
Dividend yield
0.6%
52-week
—
Next earnings
27 Oct, in 3 days

Every filing, read

last 12 months · SEC

What happened, the numbers inside, guidance and risks. The original is one click away.

29 Jul 20268-K · 2.03, 8.01HCA Inc. increased commercial paper program from $4.0B to $8.0B; notes unsecured, guaranteed by parent.open

Risks flagged

Higher leverage capacity could increase financial risk if not managed

“increased the size of its commercial paper program ... to $8.0 billion” · word for word
Read the original on SEC EDGAR ↗
28 Jul 202610-QHCA reported Q2 2026 revenue of $20.2B, up 8.7% YoY, with strong volume growth and margin improvement, though net income growth lagged at 2.8%.earningsopen

Figures in the filing · each found in the filing text

Revenues · Q2-2026$20.23B+9% y/y
Net income attributable to HCA Healthcare, Inc. · Q2-2026$1.70B+3% y/y

Risks flagged

Regulatory and reimbursement risk

“Forward-looking statements mention risks from changes in Medicare, Medicaid, and other government programs, as well as the expiration of enhanced premium tax credits.”

Labor cost pressure

“Forward-looking statements mention potential increased expenses related to labor and workforce disruptions.”

Supply chain and tariff risk

“Forward-looking statements mention potential increased expenses related to pharmaceuticals, supply chain, and tariffs.”
Read the original on SEC EDGAR ↗
24 Jul 20268-K · 2.02, 7.01, 8.01HCA reported Q2 2026 revenue of $20.23B (+8.7% YoY), Adj EBITDA $4.027B (+4.6% YoY), EPS $7.62 (+11.6% YoY). Same facility admissions +2.5%, ER visits +3.6%. Guidance revised: revenue narrowed to $77-79.5B, net income lowered to $6.3-6.7B.earningsopen

Figures in the filing · each found in the filing text

Revenue · Q2-2026$20.23B+9% y/y
Net income attributable to HCA Healthcare, Inc. · Q2-2026$1.70B+3% y/y
Diluted earnings per share · Q2-2026$7.62+12% y/y
Adjusted EBITDA · Q2-2026$4.03B+5% y/y
Cash flows from operating activities · Q2-2026$2.33B-45% y/y
Capital expenditures · Q2-2026$1.23B
Same facility admissions · Q2-20262.5%
Same facility equivalent admissions · Q2-20262.7%
Same facility emergency room visits · Q2-20263.6%
Same facility revenue per equivalent admission · Q2-20266.4%

Guidance

FY26 revenue narrowed to $77.0-79.5B from $76.5-80.0B; FY26 net income lowered to $6.3-6.7B from $6.495-7.035B

Revenue guidance narrowed slightly, net income guidance lowered due to payer mix shift and cost pressures; demand remains stable with utilization growth.

Risks flagged

Unfavorable payer mix shift due to increase in uninsured volume, impacting income before taxes by ~$400M.

“The Company estimates this payer mix shift had an unfavorable impact on income before income taxes of approximately $400 million during the second quarter.” · word for word

Guidance for net income lowered to $6.3-6.7B from $6.495-7.035B, reflecting ongoing payer mix and cost pressures.

“Revised 2026 Guidance: Net Income Attributable to HCA Healthcare, Inc. $6.300 to $6.700 billion (from $6.495 to $7.035 billion).”

Operating cash flow declined significantly to $2.335B from $4.210B in prior year, partly due to timing of Medicaid payments.

“Cash flows from operating activities totaled $2.335 billion, compared to $4.210 billion in the second quarter of 2025.” · word for word
Read the original on SEC EDGAR ↗
14 Jul 20268-K · 2.02, 7.01HCA Healthcare reported Q2 2026 preliminary results: revenue $20.230B vs $18.605B YoY; net income $1.699B vs $1.653B; Adjusted EBITDA $4.027B vs $3.849B. Same facility admissions +2.5%, ER visits +3.6%. Guidance revised: revenue narrowed toearningsopen

Figures in the filing · each found in the filing text

Revenue · Q2-2026$20.23B+9% y/y
Net income attributable to HCA Healthcare, Inc. · Q2-2026$1.70B+3% y/y
Adjusted EBITDA · Q2-2026$4.03B+5% y/y
EPS (diluted) · Q2-2026$7.62+12% y/y
Same facility admissions growth · Q2-20262.5%
Same facility equivalent admissions growth · Q2-20262.7%
Same facility emergency room visits growth · Q2-20263.6%
Same facility inpatient surgeries growth · Q2-2026-2.3%
Same facility outpatient surgeries growth · Q2-2026-3.4%

Guidance

FY26 revenue narrowed to $77.0-79.5B from $76.5-80.0B; net income lowered to $6.300-6.700B from $6.495-7.035B; Adjusted EBITDA narrowed to $15.400-16.100B from $15.550-16.450B; EPS lowered to $28.70-30.50 from $29.10-31.50; capex unchanged at $5.0-5.5B; health insurance exchanges impact revised to ($1.000)-($1.200)B from ($600)-($900)M; Medicaid supplemental programs revised to $300-500M from ($50

Guidance revised: revenue range narrowed, net income and EPS lowered due to payer mix shift from health insurance exchanges and service mix shift; partially offset by Medicaid supplemental program benefits. Capex unchanged. Management expresses confidence in navigating dynamic environment.

Risks flagged

Payer mix shift from health insurance exchanges due to coverage losses, unfavorable impact ~$400M in Q2

“The Company experienced a payer mix shift driven by an increase in uninsured volume, primarily due to patients who lost coverage on the health insurance exchanges. The Company estimates this payer mix shift had an unfavorable impact on income before income taxes of approximately $400 million during the second quarter.” · word for word

Service mix shift with declining surgical volumes (inpatient -2.3%, outpatient -3.4%)

“Same facility inpatient surgeries declined 2.3 percent, and same facility outpatient surgeries declined 3.4 percent in the second quarter of 2026 compared to the same period of 2025.” · word for word

Guidance lowered for net income and EPS due to payer mix and service mix headwinds

“Revised 2026 Guidance: Net Income $6.300 to $6.700 billion (from $6.495 to $7.035 billion); EPS $28.70 to $30.50 (from $29.10 to $31.50).”
Read the original on SEC EDGAR ↗
18 Jun 20268-K · 5.02Reported a director or officer change (departure, election, appointment or pay arrangement)SEC ↗
30 Apr 20268-K · 1.01, 2.03, 8.01HCA issued $3B in senior notes across three tranches (2031, 2033, 2036) to refinance or for general corporate purposes. No guidance or operational metrics provided.open

Risks flagged

Increased leverage from $3B debt issuance, though terms are favorable and proceeds likely for refinancing or general corporate purposes.

“took on a material direct financial obligation, increasing leverage”
Read the original on SEC EDGAR ↗
29 Apr 202610-QRevenues $19.11B (+4% y/y); Net income attributable to HCA Healthcare, Inc. $1.62B (+1% y/y); Diluted earnings per share $7.15 (+11% y/y)open

Figures in the filing · each found in the filing text

Revenues · Q1-2026$19.11B+4% y/y
Net income attributable to HCA Healthcare, Inc. · Q1-2026$1.62B+1% y/y
Diluted earnings per share · Q1-2026$7.15+11% y/y
Cash flows from operating activities · Q1-2026$2.01B+22% y/y
Purchase of property and equipment · Q1-2026$1.12B+13% y/y
Same facility revenue per equivalent admission change · Q1-20263.1%
Same facility equivalent admissions change · Q1-20261.3%
Same facility uninsured admissions change · Q1-202615.5%
Estimated cost of total uncompensated care · Q1-2026$1.25B+19% y/y
Adjusted segment EBITDA - National Group · National Group · Q1-2026$1.26B+11% y/y

Risks flagged

Uninsured patient volume increase due to policy changes

“Same facility uninsured admissions increased 15.5%, in the first quarter of 2026 compared to the first quarter of 2025, reflecting impacts from the expiration of the EPTCs at the end of 2025.” · word for word

Uncompensated care cost increase

“Estimated cost of total uncompensated care $1,252 million and $1,055 million for the quarters ended March 31, 2026 and 2025, respectively.”

Medicaid directed payment program uncertainty

“We continue to monitor pending applications to CMS regarding state Medicaid directed payment programs, including the application for the Medicaid directed payment program in the state of Florida for the program year beginning October 1, 2024 through September 30, 2025, which, if approved, could result in the recognition of additional revenues, which may be s” · word for word
Read the original on SEC EDGAR ↗
27 Apr 20268-K · 8.01Disclosed a material event under other events (litigation, recall, contract loss, or major announcement); filed financial statements and exhibits with this reportSEC ↗
24 Apr 20268-K · 2.02, 7.01, 8.01Revenues $19.11B (+4% y/y); Net income attributable to HCA Healthcare, Inc. $1.62B (+1% y/y); Diluted earnings per share $7.15 (+11% y/y)earningsopen

Figures in the filing · each found in the filing text

Revenues · Q1-2026$19.11B+4% y/y
Net income attributable to HCA Healthcare, Inc. · Q1-2026$1.62B+1% y/y
Diluted earnings per share · Q1-2026$7.15+11% y/y
Adjusted EBITDA · Q1-2026$3.80B+2% y/y
Cash flows from operating activities · Q1-2026$2.01B+22% y/y
Same facility admissions · Q1-20260.9%
Same facility equivalent admissions · Q1-20261.3%
Same facility revenue per equivalent admission · Q1-20263.1%
Capital expenditures · Q1-2026$1.12B
Dividend per share · Q1-2026$0.78

Risks flagged

Respiratory activity lower than typical; winter storm impacted volumes.

“Respiratory-related admissions were down 42 percent; winter storm in January negatively impacted first quarter volumes.” · word for word

High debt level: $48.023B total debt.

“Total debt of $48.023 billion.” · word for word
Read the original on SEC EDGAR ↗
13 Mar 2026DEF 14AHCA Healthcare filed its 2026 proxy statement (DEF 14A) detailing executive compensation, performance metrics, and governance matters.open

Figures in the filing · each found in the filing text

Adjusted EBITDA · FY2025$15.57B+12% y/y
Net income attributable to HCA Healthcare, Inc. · FY2025$6.78B+18% y/y
Total Shareholder Return (cumulative, $100 invested at 12/31/2020) · FY2025$296.34+57% y/y
Peer Group Total Shareholder Return (cumulative, $100 invested at 12/31/2020) · FY2025$148.36+15% y/y
Compensation Actually Paid to PEO · FY2025$78M+95% y/y
Average Compensation Actually Paid to non-PEO NEOs · FY2025$16M+169% y/y
CEO Pay Ratio · FY2025$420.00
Median Employee Compensation · FY2025$62955.00
Number of Employees · FY2025316,971
Frist Group Ownership Percentage · FY202532.0%

Risks flagged

Regulatory and policy uncertainty for healthcare services

“In January 2025, the Committee approved decreasing the threshold amount for performance for PSUs granted beginning in 2025 to 85% of target in response to potential policy and regulatory uncertainty for health care services.” · word for word

Key person risk due to retirement eligibility of CEO and COO

“As of December 31, 2025, Messrs. Hazen and Foster were retirement eligible under all applicable award agreements” · word for word

Concentration of ownership by Frist Group

“As of February 23, 2026, the Frist Group owned approximately 32% of our common stock through Hercules Holding, Frisco and other holdings.” · word for word
Read the original on SEC EDGAR ↗
25 Feb 20268-K · 5.02Reported the departure of a director or principal officer (CEO/CFO change); filed financial statements and exhibits with this reportSEC ↗
10 Feb 2026SC 13DSchedule 13D: Frisco Holding II 31.6%SEC ↗
10 Feb 202610-KRevenue $75.60B (+7% y/y); Net income attributable to HCA Healthcare, Inc. $6.78B (+18% y/y); Diluted EPS $28.33 (+29% y/y); Guidance: SDP revenues expected to decline in 2026; adverse effects from Exchange reforms and premium tax credit exopen

Figures in the filing · each found in the filing text

Revenue · FY2025$75.60B+7% y/y
Net income attributable to HCA Healthcare, Inc. · FY2025$6.78B+18% y/y
Diluted EPS · FY2025$28.33+29% y/y
Equivalent admissions · FY20254,107,152+3% y/y
Same facility revenue growth · FY20256.6%
Salaries and benefits as % of revenue · FY202543.5%
Admissions · FY20252,297,065+3% y/y
Medicaid SDP revenues · FY2025$6.20B+13% y/y
Professional liability reserves (net) · FY2025$2.00B-3% y/y

Guidance

SDP revenues expected to decline in 2026; adverse effects from Exchange reforms and premium tax credit expiration

Management expects headwinds from Medicaid SDP declines and Exchange reforms, but offset by resiliency efforts. No quantified guidance provided.

Risks flagged

Medicaid reimbursement reduction

“Excluding the expected impact of any additional approvals, we expect revenues from SDP arrangements to decline in 2026 compared to 2025.” · word for word

Uninsured rate increase

“We believe the expiration of the enhanced premium tax credits will adversely impact Exchange enrollment and significantly increase the uninsured rate.” · word for word

Professional liability claims severity

“A 2.5% change in the expected claim severity trend could be reasonably likely and would increase the reserve estimate by $126 million or reduce the reserve estimate by $117 million.” · word for word

Inflationary cost pressure

“We have seen inflation have a negative impact on certain of these expenses and expect inflationary pressures will continue to impact operating expenses in 2026.” · word for word
Read the original on SEC EDGAR ↗
27 Jan 20268-K · 2.02, 7.01, 8.01Revenue $19.51B (+7% y/y); Net income attributable to HCA Healthcare, Inc. $1.88B (+31% y/y); Diluted earnings per share $8.14 (+45% y/y)earningsopen

Figures in the filing · each found in the filing text

Revenue · Q4-2025$19.51B+7% y/y
Net income attributable to HCA Healthcare, Inc. · Q4-2025$1.88B+31% y/y
Diluted earnings per share · Q4-2025$8.14+45% y/y
Adjusted EBITDA · Q4-2025$4.11B+11% y/y
Cash flows from operating activities · Q4-2025$2.36B-8% y/y
Same facility admissions growth · Q4-20252.4%
Same facility equivalent admissions growth · Q4-20252.5%
Capital expenditures · Q4-2025$1.49B

Risks flagged

Operating cash flow declined 7.8% YoY due to deferred tax payments; normalized cash flow likely stronger.

“Cash flows provided by operating activities in the fourth quarter of 2025 totaled $2.359 billion compared to $2.559 billion in the fourth quarter of 2024, and were impacted by approximately $1.3 billion of estimated tax payments that were deferred to the fourth quarter of 2025” · word for word
Read the original on SEC EDGAR ↗
31 Oct 20258-K · 1.01, 2.03, 8.01Entered a material definitive agreement (acquisition, partnership, or major contract); took on a material direct financial obligation, increasing leverageopen

Risks flagged

Increased leverage from new debt issuance; terms not disclosed.

“Issuance of notes with multiple tranches; no pricing or amount disclosed.”
Read the original on SEC EDGAR ↗
30 Oct 202510-QHCA reported Q3 2025 revenue of $19.161B, up 9.6% year-over-year.earningsopen

Figures in the filing · each found in the filing text

Revenue · Q3-2025$19.16B+10% y/y

Risks flagged

Regulatory and legislative risk from OBBBA and EPTC expiration

“the impact of current and future health care public policy developments and the implementation of new, and possible changes to existing, federal, state or local laws and regulations affecting the health care industry, including the expiration of enhanced premium tax credits” · word for word

Labor cost pressure

“potential increased expenses related to labor, pharmaceuticals, supply chain or other expenditures” · word for word
Read the original on SEC EDGAR ↗
27 Oct 20258-K · 8.01Redeemed notes $1.50Bopen

Figures in the filing · each found in the filing text

redeemed_notes · point_in_time$1.50B

Risks flagged

Debt refinancing risk; new offering may have different terms.

“Proposed public offering of senior unsecured notes.”
Read the original on SEC EDGAR ↗
24 Oct 20258-K · 2.02, 7.01, 8.01Revenue $19.16B (+10% y/y); Net income attributable to HCA Healthcare, Inc. $1.64B (+29% y/y); Diluted EPS $6.96 (+43% y/y); Guidance: Revenue guidance raised to $75-76.5B from $74-76B; EPS to $27-28 from $25.50-27.00earningsopen

Figures in the filing · each found in the filing text

Revenue · Q3-2025$19.16B+10% y/y
Net income attributable to HCA Healthcare, Inc. · Q3-2025$1.64B+29% y/y
Diluted EPS · Q3-2025$6.96+43% y/y
Adjusted EBITDA · Q3-2025$3.87B+19% y/y
Cash flows from operating activities · Q3-2025$4.42B+26% y/y
Same facility admissions growth · Q3-20252.1%
Same facility equivalent admissions growth · Q3-20252.4%
Capital expenditures · Q3-2025$1.29B
Share repurchases · Q3-2025$2.50B
Dividend per share · Q4-2025$0.72

Guidance

Revenue guidance raised to $75-76.5B from $74-76B; EPS to $27-28 from $25.50-27.00

Strong volume growth, margin expansion, and raised guidance across all key metrics.

Read the original on SEC EDGAR ↗

HCA Healthcare, Inc. — questions

What did HCA Healthcare, Inc. file recently?
18 SEC filings in the last 12 months. Latest: 8-K on 2026-07-29 — HCA Inc. increased commercial paper program from $4.0B to $8.0B; notes unsecured, guaranteed by parent.

Every figure on this page comes from HCA Healthcare, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.